Literature DB >> 24358131

A genome-wide search for linkage of estimated glomerular filtration rate (eGFR) in the Family Investigation of Nephropathy and Diabetes (FIND).

Farook Thameem1, Robert P Igo2, Barry I Freedman3, Carl Langefeld3, Robert L Hanson4, Jeffrey R Schelling5, Robert C Elston2, Ravindranath Duggirala6, Susanne B Nicholas7, Katrina A B Goddard8, Jasmin Divers3, Xiuqing Guo9, Eli Ipp10, Paul L Kimmel11, Lucy A Meoni12, Vallabh O Shah13, Michael W Smith14, Cheryl A Winkler15, Philip G Zager13, William C Knowler4, Robert G Nelson4, Madeline V Pahl16, Rulan S Parekh17, W H Linda Kao12, Rebekah S Rasooly11, Sharon G Adler10, Hanna E Abboud1, Sudha K Iyengar2, John R Sedor2.   

Abstract

OBJECTIVE: Estimated glomerular filtration rate (eGFR), a measure of kidney function, is heritable, suggesting that genes influence renal function. Genes that influence eGFR have been identified through genome-wide association studies. However, family-based linkage approaches may identify loci that explain a larger proportion of the heritability. This study used genome-wide linkage and association scans to identify quantitative trait loci (QTL) that influence eGFR.
METHODS: Genome-wide linkage and sparse association scans of eGFR were performed in families ascertained by probands with advanced diabetic nephropathy (DN) from the multi-ethnic Family Investigation of Nephropathy and Diabetes (FIND) study. This study included 954 African Americans (AA), 781 American Indians (AI), 614 European Americans (EA) and 1,611 Mexican Americans (MA). A total of 3,960 FIND participants were genotyped for 6,000 single nucleotide polymorphisms (SNPs) using the Illumina Linkage IVb panel. GFR was estimated by the Modification of Diet in Renal Disease (MDRD) formula.
RESULTS: The non-parametric linkage analysis, accounting for the effects of diabetes duration and BMI, identified the strongest evidence for linkage of eGFR on chromosome 20q11 (log of the odds [LOD] = 3.34; P = 4.4 × 10(-5)) in MA and chromosome 15q12 (LOD = 2.84; P = 1.5 × 10(-4)) in EA. In all subjects, the strongest linkage signal for eGFR was detected on chromosome 10p12 (P = 5.5 × 10(-4)) at 44 cM near marker rs1339048. A subsequent association scan in both ancestry-specific groups and the entire population identified several SNPs significantly associated with eGFR across the genome.
CONCLUSION: The present study describes the localization of QTL influencing eGFR on 20q11 in MA, 15q21 in EA and 10p12 in the combined ethnic groups participating in the FIND study. Identification of causal genes/variants influencing eGFR, within these linkage and association loci, will open new avenues for functional analyses and development of novel diagnostic markers for DN.

Entities:  

Mesh:

Year:  2013        PMID: 24358131      PMCID: PMC3866106          DOI: 10.1371/journal.pone.0081888

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Diabetes mellitus is responsible for approximately 50% of cases of incident end-stage renal disease (ESRD) in the United States and other Western societies, with projections of up to 70% of ESRD in 2015 [1]. Diabetic nephropathy (DN) is a serious complication of diabetes caused by hyperglycemia-induced renal injury, involving a complex interplay of metabolic and hemodynamic disturbances in genetically predisposed individuals. DN is typically characterized by persistent proteinuria and elevated blood pressure; however, progressive declines in estimated glomerular filtration rate (eGFR, an estimate of kidney function) are uniformly present and may occur in the absence of persistent proteinuria [2]. Individuals with DN have significantly increased cardiovascular morbidity and premature mortality. Among Pima Indians with type 2 diabetes, only those with overt DN had mortality rates higher than among nondiabetic persons [3]. Rates of decline in eGFR were associated with albuminuria in type 2 diabetes [4] and assessments of eGFR facilitate the diagnosis, evaluation and management of patients with chronic kidney disease. Therefore, identifying the inherited and environmental causes of reduced eGFR would help target novel treatment strategies to prevent progression of DN to ESRD and reduce associated cardiovascular complications. Epidemiological studies demonstrate that eGFR is a complex trait, whose level in a given individual reflects contributions from genes whose expression is modulated by a hyperglycemic environment. Genome-wide linkage and association analyses have been used to localize susceptibility genes influencing eGFR. Several prior genome-wide linkage scans, including our previous genome scan in a subset of the same study subjects, identified positional candidate genes potentially influencing eGFR based on implicated chromosomal regions [5]–[15]. Recently, genome-wide association studies (GWAS) have localized common variants influencing eGFR [16]–[24]. However, these common variants account for a modest genetic contribution to variation in eGFR and related traits and their functional significance remains to be elucidated. In an attempt to identify and characterize susceptibility genes influencing kidney disease in diabetes, we chose the family-based genome-wide linkage scan approach that can identify genetic regions where there are multiple susceptibility variants or other complex mechanisms that may in aggregate explain a larger proportion of the heritability than the single polymorphisms typically identified in GWAS. A genome-wide linkage screen was performed for eGFR based on 6,000 single nucleotide polymorphisms (SNPs) from Hispanic American (HA), African American (AA), European American (EA), and American Indian (AI) participants in the Family Investigation of Nephropathy and Diabetes (FIND). The FIND study was established to provide genome-wide coverage for localization of genes with pathogenically significant effects on risk of progressive DN and related traits, such as eGFR.

Materials and Methods

Study Participants

The FIND study protocol and patient recruitment procedures have been reported [25]. Briefly, families of self-reported AA, EA, AI and MA ethnicity were recruited from eight participating investigation centers. Families were ascertained based on a proband with advanced diabetic nephropathy (DN) or DN-attributed end-stage renal disease (ESRD), who had at least one additional diabetic sibling with or without DN. A variety of metabolic, hemodynamic, anthropometric, and demographic variables were collected. Diabetes was clinically diagnosed based on treatment regimen (insulin or oral hypoglycemic agents); the remainder of study participants were screened using hemoglobin A1C levels or fasting plasma glucose concentrations. Details of the proband and sibling selection criteria have been described [14]. The Institutional Review Board at each participating center (Case Western Reserve University, Cleveland, OH, Harbor-University of California Los Angeles Medical Center, Johns Hopkins University, Baltimore, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, University of California, Los Angeles, CA, University of New Mexico, Albuquerque, NM, University of Texas Health Science Center at San Antonio, San Antonio, TX, Wake Forest School of Medicine, Winston-Salem, NC) approved all procedures, and all study subjects provided written informed consent. A certificate of confidentiality was filed at the National Institutes of Health.

Estimation of GFR

eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation (Levey et al., 1999): eGFR (ml/min per 1.73 m2) = 186×(plasma creatinine)−1.154×(age)−0.203×(0.742 if female)×(1.210 if AA). For patients with ESRD (N = 1275) receiving dialysis treatments or kidney transplants, eGFR was imputed at 5.0 ml/min/1.73 m2 because (1) eGFR is meaningless with respect to the participant's true kidney function under these circumstances; and (2) imputing at zero, an extreme value, would give the data from ESRD cases undue influence relative to those of the non-ESRD cases. A total of 3960 subjects, comprising 3547 sib pairs, were included in the analysis (Table 1).
Table 1

Summary of analyzed pedigrees and genotyped individuals (N).

Ethnic GroupPedigreesIndividualsFull-Sib PairsHalf-Sib Pairs
African American346954705149
American Indian212781708147
European American19961466226
Mexican American47816111472120
Total 1235 3960 3547 442

Genotyping

DNA was isolated from lymphoblastoid cell lines or leukocyte buffy coats [25]. The Illumina SNP-based Linkage Panel IVb was employed for both linkage and association analysis as described previously [26]. This panel consists of 6,008 diallelic SNP markers distributed evenly across the genome. The average and median intervals between markers are 482 kb (0.64 cM) and 298 kb (0.35 cM), respectively. The largest interval between successfully genotyped markers is 5.02 cM on chromosome 8, and linkage disequilibrium (LD) between markers is minimal. The mean minor allele frequency (MAF) and heterozygosity of SNP markers are 37% and 44%, respectively. Genotyping was performed at the Center for Inherited Disease Research (CIDR).

Statistical methods

Genetic analyses were performed using the S.A.G.E. (Statistical Analysis for Genetic Epidemiology) software package, version 5.3 (http://darwin.cwru.edu/sage/). Allele frequencies were estimated separately in the four ethnic groups using the maximum likelihood method implemented in the program FREQ. Mendelian inconsistencies were identified with the MARKERINFO program and inconsistent genotypes were coded as missing. Errors in relationship specification were identified with the program RELTEST. When necessary, a second relationship testing program, RELPAIR version 2.0.1, was enlisted to resolve potential errors involving complex relationships. Multipoint identity by descent (IBD) allele sharing probabilities were estimated by the method of maximum likelihood, using all available information in the pedigree as implemented in the program GENIBD. Multipoint IBD-sharing estimates are robust to misspecification of population allele frequencies, as may occur with admixed samples, because most of the parental information is inferred when the available information is high [27]. The Shannon information, as calculated by Merlin [28], available from the Illumina IV SNP panel was never less than 0.7, and seldom less than 0.8, except at the telomeric regions (data not shown). Using the multipoint IBD sharing estimates, a genome-wide linkage scan for quantitative trait loci potentially influencing eGFR was performed by the Haseman-Elston regression approach implemented within the program SIBPAL, using the W4 weighting option to maximize power. We converted the p values reported by SIBPAL to LOD scores using the one-sided chi-squared distribution with one degree of freedom (i.e., a 50∶50 mixture of distributions with 0 and 1 degrees of freedom), appropriate for a one-sided test. In principle, the sib pairs who are identical by descent (IBD) at a marker locus will be phenotypically similar for traits influenced by a nearby linked gene. Evidence for linkage of eGFR was assessed with and without incorporating covariate effects of diabetes duration and body mass index (BMI), entered in the regression model as the sibpair sum. Non-parametric multipoint linkage analysis was carried out separately in each ethnic group, and P values were combined across ethnicities according to Fisher's method [29]. Empirical P values were obtained for the major linkage peaks using the “simulation” option in SIBPAL, which performs a permutation test. Association analysis was conducted as described previously [26] using the linear mixed model approach implemented in the S.A.G.E. program ASSOC. Results were combined across ethnic groups using Fisher's method [26], [29]. The SNPs used in this analysis have been previously reported [26]. To assess the sensitivity of the association analysis to genetic admixture, the linear mixed model was fitted with and without adjustment for the first two principal components from a principal components analysis using 5,547 SNPs from the Illumina IV panel with minor allele frequencies of at least 0.05 in the combined sample. Principal components were obtained via the smartpca program in EIGENSOFT [30].

Results

Several quality control measures were implemented to determine the final set of markers for the linkage analysis. Briefly, SNPs were required to have median GenCall scores (a measure of how close a genotype is to the center of the cluster of other samples assigned to the same genotypes) ≥0.5, MAF (specific to ethnic group) ≥0.05, and p value for deviation from Hardy-Weinberg proportions >0.001. Since, LD between neighboring SNPs may create bias in estimates of IBD sharing among relatives, markers were screened such that pairwise | D′ | was less than 0.3. After quality control, a final marker set of SNPs qualifying for further genetic analysis was identified as described previously [24]. Table 1 lists the ethnicities of the 3,960 subjects comprising 3,547 sib pairs and 442 half-sib pairs from four ethnic groups in whom eGFR and genotypic data were available. Of these, 40.7%, 24.1%, 19.7%, and 15.5% were MA, AA, AI, and EA, respectively. Table 2 displays the clinical characteristics of genotyped individuals from each ethnic group.
Table 2

Clinical characteristics of the genotyped individuals.

ParametersAfrican AmericanEuropean AmericanAmerican IndianMexican American
N 9546147811611
Male324 (33.9%)276 (44.8%)298 (38.2%)686 (42.6%)
Age (years)59 (51, 67)62 (53, 70)53 (46, 61)57 (49, 65)
Diabetes duration (years)18 (11, 25)18 (11, 26)16 (4, 25)15 (7, 22)
BMI (kg/m2)32 (27, 37)30 (26, 36)32 (27, 37)30 (26, 34)
HbA1c (%)7.1 (6.2, 8.6)7.0 (6.2, 8.0)7.5 (6.3, 9.3)7.5 (6.4, 9.1)
Urine ACR (g/g)0.15 (0.01, 3.00)0.05 (0.01, 1.33)0.13 (0.02, 3.00)0.05 (0.01, 1.53)
Urine PCR (g/g)0.31 (0.06, 3.50)0.21 (0.06, 2.00)0.37 (0.09, 3.50)0.18 (0.05, 2.20)
eGFR (ml/min per 1.73 m2)46.6 (5.0, 83.0)52.2 (5.0, 77.9)60.5 (5.0, 97.4)69.1 (5.0, 100.3)

ACR-Albumin:Creatinine Ratio; PCR-Protein:Creatinine Ratio; eGFR-estimated Glomerular Filtration Rate using modified MDRD equation Values are expressed as either N (%) or median (1st quartile, 3rd quartile).

ACR-Albumin:Creatinine Ratio; PCR-Protein:Creatinine Ratio; eGFR-estimated Glomerular Filtration Rate using modified MDRD equation Values are expressed as either N (%) or median (1st quartile, 3rd quartile).

Genome-wide linkage scans for eGFR

Adjusting for the covariate effects of diabetes duration and BMI, the genome-wide linkage scan in population-combined data identified the strongest evidence for linkage of eGFR on chromosome 10p12.31 (P = 5.5×10−4) at 44 cM near rs1339048 (Figures 1, 2a and Table 3). Evidence for linkage was primarily contributed by the AA and EA groups, with a smaller contribution from MA. A second suggestive linkage signal across populations was observed on chromosome 20q11 at 56 cM (P = 1.9×10−3), flanked by SNPs rs221972 and rs735264 (Figure 1; Table 3).
Figure 1

This figure shows the results of the genome-wide linkage scan for eGFR in population-specific and population-combined analysis that accounted the covariate effects of BMI and diabetes duration.

AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans, cM-Centi Morgans.

Figure 2

Figure 2a. The figure shows the linkage of eGFR on 10p12 after accounting for the covariate effects of BMI and diabetes duration in the population-specific and combined analysis. A black dot denotes the location of rs1345561 (62.24 cM) that is associated with eGFR in African American participants (P  =  3.1 × 10−4) after accounting for the covariate effects of BMI and diabetes duration. AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans, cM-Centi Morgans. Figure 2b.The figure shows the linkage of eGFR on 20q11 after accounting for the covariate effects of BMI and diabetes duration in the population-specific and combined analysis. The green and black dots denote the location of rs1885567 (43.47 cM) rs968478 (75.75 cM) that are associated with eGFR in MA (P  =  0034) and AA (P = 0.0018) respectively. AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans; cM-Centi Morgans.

Table 3

Major linkage peaks identified for the eGFR in population-specific and in population-combined analysis.

Chr.GroupcMMarker p, BaselineLOD, Baseline p, CovariatesLOD, CovariatesFlanking Markers
1MA259.4rs15378024.7×10−4 2.386.2×10−4 2.26rs1341446, rs1342872
2EA183.7rs9638546.0×10−3 1.373.9×10−2 0.67rs2007326, rs1002207
AA187.8rs7670421.1×10−3 2.041.5×10−3 1.91rs8899060, rs2012128
3EA107.8rs15626261.4×10−2 1.057.5×10−4 2.19rs1470797, rs1494302
7MA78.4rs14685881.0×10−3 2.077.5×10−4 2.19rs1874243, rs678798
10EA26.6rs9133751.9×10−4 2.748.1×10−4 2.16rs1033912, rs1535976
All43.9rs13390481.2×10−3 5.5×10−4 rs7292450, rs949857
15EA11.1rs29287141.2×10−3 2.001.5×10−4 2.84rs3922665, rs1862359
20MA56.8rs7362643.5×10−5 3.434.4×10−5 3.34rs2219720, rs663550
All56.02.2×10−3 1.9×10−3 rs2219720, rs735264

Group, ethnic group (AA = African American, AI = American Indian, EA = European American, MA = Mexican American); cM, centimorgans on the deCODE linkage map; Baseline, eGFR without covariate adjustment; Covariates, eGFR adjusted for BMI and diabetes duration. Reported p values are asymptotic.

This figure shows the results of the genome-wide linkage scan for eGFR in population-specific and population-combined analysis that accounted the covariate effects of BMI and diabetes duration.

AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans, cM-Centi Morgans. Figure 2a. The figure shows the linkage of eGFR on 10p12 after accounting for the covariate effects of BMI and diabetes duration in the population-specific and combined analysis. A black dot denotes the location of rs1345561 (62.24 cM) that is associated with eGFR in African American participants (P  =  3.1 × 10−4) after accounting for the covariate effects of BMI and diabetes duration. AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans, cM-Centi Morgans. Figure 2b.The figure shows the linkage of eGFR on 20q11 after accounting for the covariate effects of BMI and diabetes duration in the population-specific and combined analysis. The green and black dots denote the location of rs1885567 (43.47 cM) rs968478 (75.75 cM) that are associated with eGFR in MA (P  =  0034) and AA (P = 0.0018) respectively. AA-African Americans; AI-American Indians; EA-European Americans; MA-Mexican Americans; cM-Centi Morgans. Group, ethnic group (AA = African American, AI = American Indian, EA = European American, MA = Mexican American); cM, centimorgans on the deCODE linkage map; Baseline, eGFR without covariate adjustment; Covariates, eGFR adjusted for BMI and diabetes duration. Reported p values are asymptotic. In population-specific analysis, the strongest evidence for linkage of eGFR localized to a genetic region on 20q11.22 at 56.8 cM near rs736264 (LOD = 3.34; P = 4.4×10−5) in MA participants (Figures 1, 2b). Other genetic regions with suggestive evidence for eGFR linkage in MA included 1q43 and 7q11.22 (Figure 1; Table 3). Accounting for the covariate effects of diabetes duration and BMI, the Haseman-Elston linkage scan in EA identified the strongest linkage signal for eGFR on chromosomes 15q12 near rs2928714 (LOD = 2.84; P = 1.5×10−4) and suggestive evidence for linkage was found near rs913375 on 10p14 (Figure 1; Table 3).

Genome-wide association scans for eGFR

Following the linkage scans, coarse association analyses between eGFR and SNPs that passed quality control was performed, using the approach implemented in ASSOC. Table 4 shows the SNPs associated with eGFR with p<0.001 in at least one ethnic group after adjusting for the covariate effects of diabetes duration and BMI in population-specific or population-combined analyses. In the population-combined data, the most significant association with eGFR was found for rs486567 on chromosome 1q21.1 (P = 2.9×10−4), primarily contributed by EA (Table 4). We also observed a significant association between rs580839 residing on 15q14 and eGFR (P = 4.2×10−4) in the combined data, that was primarily driven by AI (Table 4). Our association analysis in the population combined data also exhibited a significant association between rs856830 residing on 6q12 and eGFR (P = 4.3×10−4), which was driven by AA, AI and MA. Another SNP (rs1345561) associated with eGFR (P = 6.4×10−4) in the combined data was located approximately 16 Mb from the eGFR linkage marker rs1339048 on 10p12 (Table 4; Figure 2). This association in the combined data was primarily driven by AA (Table 4). Several SNPs were significantly associated with eGFR in population-specific analyses, the most significant were rs1703711 residing on chromosome 10q26.3 (P = 2.96×10−4), rs580839 on 15q14 (P = 4.81×10−5), rs666478 on 9p21 (P = 1.46×10−4) and rs2928972 on 18q21.2 (P = 1.30×10−4) in AA, AI, EA, and MA, respectively (Table 4). These results were robust to ethnic admixture: no P value changed by more than 2-fold, and the vast majority of P values changed by less than 1.1-fold, with adjustment for two principal components from a genomewide principal components analysis (data not shown).
Table 4

Most significantly associated SNPs with eGFR in population-specific and in population-combined analysis.

ChromSNPPositioncMPopulation-SpecificPopulation- Combined
AAAIEAMA
P values*
1rs486567101340030122.630.180395NA0.00031040.0539860.00029
1rs767707164292200169.230.0009140.0523170.41054590.9304390.00526
2rs16864301089839927.830.0007880.4353200.46045370.9678600.02468
2rs17344491090088227.830.0006980.4472580.41859450.9970080.02205
4rs9254702569225544.720.0003870.2296510.57957430.2240380.00372
4rs19659078879535595.340.9304390.0006880.68080460.3676870.02550
4rs1516822153687906146.150.4171570.0003960.41768660.4137090.00734
5rs878953163859070168.790.5374830.0125370.19263910.0015830.00097
5rs6879805173474434191.160.7241790.8210730.00061160.2929650.01913
6rs741111589458134.880.4126050.1867920.93420050.0009650.01408
6rs69017501712740538.030.8942380.5085910.00038410.2127870.00892
6rs21804192183629643.940.3381710.3710590.85969550.0002750.00755
6rs8568306834007883.080.0079000.0321000.28155360.0101680.00043
8rs19048992150039637.40.0004280.6467850.60824000.0201440.00144
8rs1019603113816992116.330.2174850.0008240.21689220.7661970.00758
9rs6664782716318049.590.5192310.2052880.00014590.9458440.00447
9rs70377448998326994.080.0283850.0046700.10164640.0535140.00042
10rs13455613581062862.240.0003090.1790330.06640670.3308810.00064
10rs1703711132531704171.590.0002960.4710690.86482500.3098650.00896
11rs14918462785559044.560.8225560.4445310.98690610.0001910.01400
12rs142072526218445.60.7973476.86E-050.55059000.3381560.00338
14rs7620635216865249.940.9502090.2502650.00058240.9298300.02188
15rs5808393278612131.860.2715914.81E-050.53481900.1025670.00042
15rs114576167343265.780.0146210.0005650.77207840.4440030.00125
18rs29289274767718373.730.6967730.8811540.19556810.0001290.00464
18rs90650770889709108.450.6517000.3522130.00057170.2365230.00781
19rs1715093350578312.180.0004490.3616670.67978230.4879330.01171

SNPs with at least one p value less than 0.001 in an ethnic-specific or in the overall analysis are shown. Chrom, Chromosome; SNP, Single Nucleotide Polymorphism; cM, centimorgans; AA, African American; AI, American Indian; EA, European American; MA, Mexican American; NA, Not applicable;

*, Adjusted for the covariate effects of BMI and diabetes duration.

SNPs with at least one p value less than 0.001 in an ethnic-specific or in the overall analysis are shown. Chrom, Chromosome; SNP, Single Nucleotide Polymorphism; cM, centimorgans; AA, African American; AI, American Indian; EA, European American; MA, Mexican American; NA, Not applicable; *, Adjusted for the covariate effects of BMI and diabetes duration.

Discussion

Estimated GFR provides an accurate index of the degree of renal dysfunction and plays a prominent role in the staging of chronic kidney disease [31]. Though variation in eGFR among individuals is partly explained by environmental influences, heritability estimates of eGFR in families suggest that genes play a major role in determining kidney function [32]. Despite high heritability estimates, the identification of genes influencing eGFR and its variability remains challenging. In attempts to identify quantitative trait loci influencing eGFR, the genome-wide linkage approach has been utilized in several genetic epidemiological studies [32]. Genome wide linkage studies have identified several QTL influencing eGFR, but the subsequent susceptibility gene mapping efforts have been unsuccessful and remain in progress. In an effort to identify and characterize the genes influencing kidney function, we performed a SNP-based genome-wide linkage scan followed by association analysis in the multi-ethnic FIND samples. The most significant linkage to eGFR in ethnicity-combined data was found near rs1339048 on 10p12.31 (P = 5.5×10−4). It is interesting to note that the linkage of eGFR on 10p12 was contributed by three (AA, EA, and MA) of the four ethnic groups participating in this study, indicating that the 10p12 region may potentially harbor genes influencing GFR in the FIND participants (Figures 1 and 2a; Table 3). The localization of an eGFR linkage signal in the 10p12 region appears to be novel as this region was not identified in the previous genome-wide microsatellite scan studies for eGFR, including in the FIND [14]. However, several genome-wide microsatellite linkage scans have linked this 10p12 region with obesity and related traits. Furthermore, genes located near the eGFR linkage markers on 10p12, including calcium channel, voltage-dependent, beta 2 subunit (CACNB2), ARL5B ADP-ribosylation factor-like 5B (ARL5), and nebulette (NEBL), were previously associated with eGFR-related traits such as blood pressure and hypertension [33], sudden cardiac arrest and diabetic retinopathy [34]. By binding to actin and thin filaments and Z-line associated proteins in striated cardiac muscle, nubulette regulates cardiac myofibril assembly. CACNB2 is a subunit of a voltage-dependent calcium channel protein and mutations in CACNB2 were also associated with sudden cardiac arrest. In population-specific linkage analyses, suggestive evidence for linkage of eGFR was seen at rs736264 on 20q11.22 in MA (Fig. 2b) and at rs2928714 on 15q12 in EA. Although our results failed to replicate genetic regions previously linked to eGFR and related traits in the FIND and non-FIND studies and appeared to detect novel loci influencing eGFR, the 15p12 region has been previously associated with urine albumin∶creatinine ratio (ACR) in MA in the San Antonio Family Diabetes Study [35]. We next performed a sparse association scan to identify whether the SNPs used in the linkage scan are associated with eGFR and potentially responsible for the observed linkage signals. While several SNPs across the genome were suggestively associated with eGFR, none of them were located within the eGFR linkage intervals identified in population-specific or the combined data set. In the population-combined association analysis, the most significant association was observed between eGFR and rs486567, rs580839, and rs1345561 with primary contributors EA, AI, and AA, respectively (Table 4). The rs1345561 SNP is located ∼16 Mb from the linkage of eGFR marker rs1339048 on 10p12 that was primarily driven by AA (Figure 2a; Table 4). The most significant population-specific associations with eGFR were found for rs1703711, rs580839, rs666478, and rs2928972 in AA, AI, EA, and MA, respectively (Table 4). Of the SNPs most strongly associated with eGFR in population-specific analyses, rs666478 is located within an intronic region of the tyrosine kinase receptor (TEK) gene on 9p21. TEK is a cell-surface receptor for angiopoietin (ANGPT) 1, 2, and 4. Through TEK-dependent signaling, ANGPT regulates endothelial cell survival, proliferation, migration, adhesion and cell spreading, and controls vascular permeability and quiescence. Mutations in TEK were previously associated with autosomal dominant forms of venous malformations [36]. Although the functional relevance of rs666478 associating with eGFR needs to be explored, genetic variants located about 5 Mb upstream of TEK on cyclin-dependent kinase inhibitor (CDKN) 2A, 2B genes have been previously associated with type 2 diabetes mellitus [37] and coronary heart disease [38]. Population-specific association analysis identified several SNPs (rs1686430 and rs1734449) that are associated with GFR only in the AA group. They were located 100 kb apart within an intronic region of the protein disulfide isomerase family A, member 6 (PDIA6) gene on 2p25. PDIA6 belongs to a thioredoxin superfamily oxidoreductase from the endoplasmic reticulum that acts as a redox signaling adaptor protein, adjusting reactive oxygen species intermediates to specific signals and redox signals to cell homeostasis [39]. It also catalyzes the formation and isomerization of disulfide bonds thereby facilitating protein folding. Although the functional mechanism by which these two variants residing within the PDIA6 and regulating renal function needs to be examined, genetic variants located about 7 Mb upstream of PDIA6 on the SRY (sex determining region Y)-box 11 (SOX11) gene were previously associated with T2DM and CKD in Europeans [17]. Utilizing a relatively dense set of 6,000 SNPs as a linkage panel as opposed to the conventional use of a set of about 400 microsatellite markers, the present study reveals quantitative trait loci influencing eGFR to 20q11 in MA, 15q21 in EA and 10p12 in the combined ethnic groups from the FIND study. Several suggestive linkage peaks were also identified in population-specific and population-combined linkage scans in this multi-ethnic cohort. In contrast to GWAS that requires a very stringent p-values (e.g., P<5×10−8) for statistical significance on account of the large number of statistical tests involved, linkage studies with less stringent P values are powerful because the number of effectively independent comparisons is much smaller. Conventionally p<0.0001 (LOD>3) has been considered significant linkage, while p<0.001 (LOD>2) has been considered suggestive [40]. Furthermore, the linkage approach can identify potential genetic regions harboring multiple susceptibility variants or other complex mechanisms that may in aggregate explain a larger proportion of the heritability than the single polymorphisms typically identified in GWAS. As expected for a complex trait, multiple linkage peaks for eGFR were observed. Although the functional relevance of the linkage findings remains to be established and replicated, genetic regions suggestively linked with eGFR in population-specific and population-combined studies suggest that multiple loci are involved in regulating eGFR in diabetes. Disappointingly, there was no significant overlap with loci linked with renal function-related traits in other studies [5]–[13], as well as in our previous FIND microsatellite marker linkage study that was carried out in a subset of the same study populations [14]. Absence of concordance in localizing QTL influencing eGFR between the present study and our previous study [14] using the same FIND population data set could be due to the differences in the sample size, set of linkage markers and covariates used. In contrast to our previous linkage scan for eGFR [14] that used the genotypic data of about 400 microsatellite markers and eGFR data available on 941 individuals and 882 sib pairs, the present study used genotypic data of about 6000 SNPs and eGFR data available on 3960 individuals and 3547 sib pairs. In addition, the previous study accounted for the diabetes duration and angiotensin converting enzyme inhibitor/angiotensin receptor blocker use as covariates in the linkage analysis [14]. The present study used the effects of BMI, and diabetes duration in the eGFR linkage scan. A limitation of the present analysis of eGFR as a continuous variable is that many of the determinants of high eGFR, such as uncontrolled hyperglycemia before diabetes treatment is optimized, may not be under genetic control or may be influenced by different genetic factors than those contributing to declining eGFR. This might, in part, account for differences in the present linkage results with those from analysis of diabetic nephropathy as a discrete trait [30]. The discrepancies between the present study and the non-FIND study results [5]–[13] may be related, in part, to heterogeneous study populations (some with and some lacking diabetes), pedigree structures, ascertainment criteria, treatment effects, definitions of kidney function, and diabetes duration. In contrast to existing publications, the FIND is a multi-ethnic collection of families ascertained based on a proband with advanced DN or ESRD with at least one other diabetic sibling with or without nephropathy. Furthermore, differences in allele frequencies and LD structure of the sets of SNPs contributing to linkage and association might have contributed to the lack of consistency across ethnic groups. While this large study in a severely affected study sample had several advantages, potential limitations are that eGFR was estimated using a single random blood sample for serum creatinine concentration and employed the modified MDRD equation. This equation performs best for eGFR <60 ml/min per 1.73 m2; whereas the CKD-EPI equation appears more accurate for those with eGFR values between 60 and 90 ml/min per 1.73 m2. Although all analyses adjusted for diabetes duration and BMI, other potentially relevant confounding variables such as degree of blood pressure control and cardiovascular disease risk factors were unavailable. In conclusion, several loci influencing eGFR were identified in the multi-ethnic FIND cohort. Linkage and association results emanating from this multi-ethnic study represent a first step towards improving our knowledge of the mechanisms underlying genetic susceptibility to renal function in diabetes. Furthermore, the results of linkage and association analyses reported in this study will help interpret future genome-wide association/whole-genome sequencing data that should accelerate the identification of causal genes for variation in kidney function in patients with diabetes. Defining the genetic architecture responsible for eGFR loss in individuals of different ethnicities may help develop ethnicity-specific intervention programs and services specifically targeted toward this devastating complication of diabetes. With existing high-throughput genome technologies and novel statistical methodologies, we envision promising new therapies to prevent loss of eGFR, a strong and independent risk factor for cardiovascular morbidity and mortality in patients with diabetes.
  38 in total

1.  Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.

Authors:  Vinciane Wouters; Nisha Limaye; Melanie Uebelhoer; Alexandre Irrthum; Laurence M Boon; John B Mulliken; Odile Enjolras; Eulalia Baselga; Jonathan Berg; Anne Dompmartin; Sten A Ivarsson; Loshan Kangesu; Yves Lacassie; Jill Murphy; Ahmad S Teebi; Anthony Penington; Paul Rieu; Miikka Vikkula
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

Review 2.  Need for better diabetes treatment for improved renal outcome.

Authors:  Peter Rossing; Dick de Zeeuw
Journal:  Kidney Int Suppl       Date:  2011-03       Impact factor: 10.545

3.  Genome-wide association study of diabetic retinopathy in a Taiwanese population.

Authors:  Yu-Chuen Huang; Jane-Ming Lin; Hui-Ju Lin; Ching-Chu Chen; Shih-Yin Chen; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Ophthalmology       Date:  2011-02-18       Impact factor: 12.079

4.  Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study.

Authors:  Robert P Igo; Sudha K Iyengar; Susanne B Nicholas; Katrina A B Goddard; Carl D Langefeld; Robert L Hanson; Ravindranath Duggirala; Jasmin Divers; Hanna Abboud; Sharon G Adler; Nedal H Arar; Amanda Horvath; Robert C Elston; Donald W Bowden; Xiuqing Guo; Eli Ipp; W H Linda Kao; Paul L Kimmel; William C Knowler; Lucy A Meoni; Julio Molineros; Robert G Nelson; Madeline V Pahl; Rulan S Parekh; Rebekah S Rasooly; Jeffrey R Schelling; Vallabh O Shah; Michael W Smith; Cheryl A Winkler; Philip G Zager; John R Sedor; Barry I Freedman
Journal:  Am J Nephrol       Date:  2011-03-31       Impact factor: 3.754

5.  Temporal trends in the prevalence of diabetic kidney disease in the United States.

Authors:  Ian H de Boer; Tessa C Rue; Yoshio N Hall; Patrick J Heagerty; Noel S Weiss; Jonathan Himmelfarb
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

6.  Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure.

Authors:  Louise V Wain; Germaine C Verwoert; Paul F O'Reilly; Gang Shi; Toby Johnson; Andrew D Johnson; Murielle Bochud; Kenneth M Rice; Peter Henneman; Albert V Smith; Georg B Ehret; Najaf Amin; Martin G Larson; Vincent Mooser; David Hadley; Marcus Dörr; Joshua C Bis; Thor Aspelund; Tõnu Esko; A Cecile J W Janssens; Jing Hua Zhao; Simon Heath; Maris Laan; Jingyuan Fu; Giorgio Pistis; Jian'an Luan; Pankaj Arora; Gavin Lucas; Nicola Pirastu; Irene Pichler; Anne U Jackson; Rebecca J Webster; Feng Zhang; John F Peden; Helena Schmidt; Toshiko Tanaka; Harry Campbell; Wilmar Igl; Yuri Milaneschi; Jouke-Jan Hottenga; Veronique Vitart; Daniel I Chasman; Stella Trompet; Jennifer L Bragg-Gresham; Behrooz Z Alizadeh; John C Chambers; Xiuqing Guo; Terho Lehtimäki; Brigitte Kühnel; Lorna M Lopez; Ozren Polašek; Mladen Boban; Christopher P Nelson; Alanna C Morrison; Vasyl Pihur; Santhi K Ganesh; Albert Hofman; Suman Kundu; Francesco U S Mattace-Raso; Fernando Rivadeneira; Eric J G Sijbrands; Andre G Uitterlinden; Shih-Jen Hwang; Ramachandran S Vasan; Thomas J Wang; Sven Bergmann; Peter Vollenweider; Gérard Waeber; Jaana Laitinen; Anneli Pouta; Paavo Zitting; Wendy L McArdle; Heyo K Kroemer; Uwe Völker; Henry Völzke; Nicole L Glazer; Kent D Taylor; Tamara B Harris; Helene Alavere; Toomas Haller; Aime Keis; Mari-Liis Tammesoo; Yurii Aulchenko; Inês Barroso; Kay-Tee Khaw; Pilar Galan; Serge Hercberg; Mark Lathrop; Susana Eyheramendy; Elin Org; Siim Sõber; Xiaowen Lu; Ilja M Nolte; Brenda W Penninx; Tanguy Corre; Corrado Masciullo; Cinzia Sala; Leif Groop; Benjamin F Voight; Olle Melander; Christopher J O'Donnell; Veikko Salomaa; Adamo Pio d'Adamo; Antonella Fabretto; Flavio Faletra; Sheila Ulivi; Fabiola M Del Greco; Maurizio Facheris; Francis S Collins; Richard N Bergman; John P Beilby; Joseph Hung; A William Musk; Massimo Mangino; So-Youn Shin; Nicole Soranzo; Hugh Watkins; Anuj Goel; Anders Hamsten; Pierre Gider; Marisa Loitfelder; Marion Zeginigg; Dena Hernandez; Samer S Najjar; Pau Navarro; Sarah H Wild; Anna Maria Corsi; Andrew Singleton; Eco J C de Geus; Gonneke Willemsen; Alex N Parker; Lynda M Rose; Brendan Buckley; David Stott; Marco Orru; Manuela Uda; Melanie M van der Klauw; Weihua Zhang; Xinzhong Li; James Scott; Yii-Der Ida Chen; Gregory L Burke; Mika Kähönen; Jorma Viikari; Angela Döring; Thomas Meitinger; Gail Davies; John M Starr; Valur Emilsson; Andrew Plump; Jan H Lindeman; Peter A C 't Hoen; Inke R König; Janine F Felix; Robert Clarke; Jemma C Hopewell; Halit Ongen; Monique Breteler; Stéphanie Debette; Anita L Destefano; Myriam Fornage; Gary F Mitchell; Nicholas L Smith; Hilma Holm; Kari Stefansson; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Nilesh J Samani; Michael Preuss; Igor Rudan; Caroline Hayward; Ian J Deary; H-Erich Wichmann; Olli T Raitakari; Walter Palmas; Jaspal S Kooner; Ronald P Stolk; J Wouter Jukema; Alan F Wright; Dorret I Boomsma; Stefania Bandinelli; Ulf B Gyllensten; James F Wilson; Luigi Ferrucci; Reinhold Schmidt; Martin Farrall; Tim D Spector; Lyle J Palmer; Jaakko Tuomilehto; Arne Pfeufer; Paolo Gasparini; David Siscovick; David Altshuler; Ruth J F Loos; Daniela Toniolo; Harold Snieder; Christian Gieger; Pierre Meneton; Nicholas J Wareham; Ben A Oostra; Andres Metspalu; Lenore Launer; Rainer Rettig; David P Strachan; Jacques S Beckmann; Jacqueline C M Witteman; Jeanette Erdmann; Ko Willems van Dijk; Eric Boerwinkle; Michael Boehnke; Paul M Ridker; Marjo-Riitta Jarvelin; Aravinda Chakravarti; Goncalo R Abecasis; Vilmundur Gudnason; Christopher Newton-Cheh; Daniel Levy; Patricia B Munroe; Bruce M Psaty; Mark J Caulfield; Dabeeru C Rao; Martin D Tobin; Paul Elliott; Cornelia M van Duijn
Journal:  Nat Genet       Date:  2011-09-11       Impact factor: 38.330

7.  Genetic association for renal traits among participants of African ancestry reveals new loci for renal function.

Authors:  Ching-Ti Liu; Maija K Garnaas; Adrienne Tin; Anna Kottgen; Nora Franceschini; Carmen A Peralta; Ian H de Boer; Xiaoning Lu; Elizabeth Atkinson; Jingzhong Ding; Michael Nalls; Daniel Shriner; Josef Coresh; Abdullah Kutlar; Kirsten Bibbins-Domingo; David Siscovick; Ermeg Akylbekova; Sharon Wyatt; Brad Astor; Josef Mychaleckjy; Man Li; Muredach P Reilly; Raymond R Townsend; Adebowale Adeyemo; Alan B Zonderman; Mariza de Andrade; Stephen T Turner; Thomas H Mosley; Tamara B Harris; Charles N Rotimi; Yongmei Liu; Sharon L R Kardia; Michele K Evans; Michael G Shlipak; Holly Kramer; Michael F Flessner; Albert W Dreisbach; Wolfram Goessling; L Adrienne Cupples; W Linda Kao; Caroline S Fox
Journal:  PLoS Genet       Date:  2011-09-08       Impact factor: 5.917

8.  Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD.

Authors:  Carsten A Böger; Mathias Gorski; Man Li; Michael M Hoffmann; Chunmei Huang; Qiong Yang; Alexander Teumer; Vera Krane; Conall M O'Seaghdha; Zoltán Kutalik; H-Erich Wichmann; Thomas Haak; Eva Boes; Stefan Coassin; Josef Coresh; Barbara Kollerits; Margot Haun; Bernhard Paulweber; Anna Köttgen; Guo Li; Michael G Shlipak; Neil Powe; Shih-Jen Hwang; Abbas Dehghan; Fernando Rivadeneira; André Uitterlinden; Albert Hofman; Jacques S Beckmann; Bernhard K Krämer; Jacqueline Witteman; Murielle Bochud; David Siscovick; Rainer Rettig; Florian Kronenberg; Christoph Wanner; Ravi I Thadhani; Iris M Heid; Caroline S Fox; W H Kao
Journal:  PLoS Genet       Date:  2011-09-29       Impact factor: 5.917

9.  Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk.

Authors:  Georg B Ehret; Patricia B Munroe; Kenneth M Rice; Murielle Bochud; Andrew D Johnson; Daniel I Chasman; Albert V Smith; Martin D Tobin; Germaine C Verwoert; Shih-Jen Hwang; Vasyl Pihur; Peter Vollenweider; Paul F O'Reilly; Najaf Amin; Jennifer L Bragg-Gresham; Alexander Teumer; Nicole L Glazer; Lenore Launer; Jing Hua Zhao; Yurii Aulchenko; Simon Heath; Siim Sõber; Afshin Parsa; Jian'an Luan; Pankaj Arora; Abbas Dehghan; Feng Zhang; Gavin Lucas; Andrew A Hicks; Anne U Jackson; John F Peden; Toshiko Tanaka; Sarah H Wild; Igor Rudan; Wilmar Igl; Yuri Milaneschi; Alex N Parker; Cristiano Fava; John C Chambers; Ervin R Fox; Meena Kumari; Min Jin Go; Pim van der Harst; Wen Hong Linda Kao; Marketa Sjögren; D G Vinay; Myriam Alexander; Yasuharu Tabara; Sue Shaw-Hawkins; Peter H Whincup; Yongmei Liu; Gang Shi; Johanna Kuusisto; Bamidele Tayo; Mark Seielstad; Xueling Sim; Khanh-Dung Hoang Nguyen; Terho Lehtimäki; Giuseppe Matullo; Ying Wu; Tom R Gaunt; N Charlotte Onland-Moret; Matthew N Cooper; Carl G P Platou; Elin Org; Rebecca Hardy; Santosh Dahgam; Jutta Palmen; Veronique Vitart; Peter S Braund; Tatiana Kuznetsova; Cuno S P M Uiterwaal; Adebowale Adeyemo; Walter Palmas; Harry Campbell; Barbara Ludwig; Maciej Tomaszewski; Ioanna Tzoulaki; Nicholette D Palmer; Thor Aspelund; Melissa Garcia; Yen-Pei C Chang; Jeffrey R O'Connell; Nanette I Steinle; Diederick E Grobbee; Dan E Arking; Sharon L Kardia; Alanna C Morrison; Dena Hernandez; Samer Najjar; Wendy L McArdle; David Hadley; Morris J Brown; John M Connell; Aroon D Hingorani; Ian N M Day; Debbie A Lawlor; John P Beilby; Robert W Lawrence; Robert Clarke; Jemma C Hopewell; Halit Ongen; Albert W Dreisbach; Yali Li; J Hunter Young; Joshua C Bis; Mika Kähönen; Jorma Viikari; Linda S Adair; Nanette R Lee; Ming-Huei Chen; Matthias Olden; Cristian Pattaro; Judith A Hoffman Bolton; Anna Köttgen; Sven Bergmann; Vincent Mooser; Nish Chaturvedi; Timothy M Frayling; Muhammad Islam; Tazeen H Jafar; Jeanette Erdmann; Smita R Kulkarni; Stefan R Bornstein; Jürgen Grässler; Leif Groop; Benjamin F Voight; Johannes Kettunen; Philip Howard; Andrew Taylor; Simonetta Guarrera; Fulvio Ricceri; Valur Emilsson; Andrew Plump; Inês Barroso; Kay-Tee Khaw; Alan B Weder; Steven C Hunt; Yan V Sun; Richard N Bergman; Francis S Collins; Lori L Bonnycastle; Laura J Scott; Heather M Stringham; Leena Peltonen; Markus Perola; Erkki Vartiainen; Stefan-Martin Brand; Jan A Staessen; Thomas J Wang; Paul R Burton; Maria Soler Artigas; Yanbin Dong; Harold Snieder; Xiaoling Wang; Haidong Zhu; Kurt K Lohman; Megan E Rudock; Susan R Heckbert; Nicholas L Smith; Kerri L Wiggins; Ayo Doumatey; Daniel Shriner; Gudrun Veldre; Margus Viigimaa; Sanjay Kinra; Dorairaj Prabhakaran; Vikal Tripathy; Carl D Langefeld; Annika Rosengren; Dag S Thelle; Anna Maria Corsi; Andrew Singleton; Terrence Forrester; Gina Hilton; Colin A McKenzie; Tunde Salako; Naoharu Iwai; Yoshikuni Kita; Toshio Ogihara; Takayoshi Ohkubo; Tomonori Okamura; Hirotsugu Ueshima; Satoshi Umemura; Susana Eyheramendy; Thomas Meitinger; H-Erich Wichmann; Yoon Shin Cho; Hyung-Lae Kim; Jong-Young Lee; James Scott; Joban S Sehmi; Weihua Zhang; Bo Hedblad; Peter Nilsson; George Davey Smith; Andrew Wong; Narisu Narisu; Alena Stančáková; Leslie J Raffel; Jie Yao; Sekar Kathiresan; Christopher J O'Donnell; Stephen M Schwartz; M Arfan Ikram; W T Longstreth; Thomas H Mosley; Sudha Seshadri; Nick R G Shrine; Louise V Wain; Mario A Morken; Amy J Swift; Jaana Laitinen; Inga Prokopenko; Paavo Zitting; Jackie A Cooper; Steve E Humphries; John Danesh; Asif Rasheed; Anuj Goel; Anders Hamsten; Hugh Watkins; Stephan J L Bakker; Wiek H van Gilst; Charles S Janipalli; K Radha Mani; Chittaranjan S Yajnik; Albert Hofman; Francesco U S Mattace-Raso; Ben A Oostra; Ayse Demirkan; Aaron Isaacs; Fernando Rivadeneira; Edward G Lakatta; Marco Orru; Angelo Scuteri; Mika Ala-Korpela; Antti J Kangas; Leo-Pekka Lyytikäinen; Pasi Soininen; Taru Tukiainen; Peter Würtz; Rick Twee-Hee Ong; Marcus Dörr; Heyo K Kroemer; Uwe Völker; Henry Völzke; Pilar Galan; Serge Hercberg; Mark Lathrop; Diana Zelenika; Panos Deloukas; Massimo Mangino; Tim D Spector; Guangju Zhai; James F Meschia; Michael A Nalls; Pankaj Sharma; Janos Terzic; M V Kranthi Kumar; Matthew Denniff; Ewa Zukowska-Szczechowska; Lynne E Wagenknecht; F Gerald R Fowkes; Fadi J Charchar; Peter E H Schwarz; Caroline Hayward; Xiuqing Guo; Charles Rotimi; Michiel L Bots; Eva Brand; Nilesh J Samani; Ozren Polasek; Philippa J Talmud; Fredrik Nyberg; Diana Kuh; Maris Laan; Kristian Hveem; Lyle J Palmer; Yvonne T van der Schouw; Juan P Casas; Karen L Mohlke; Paolo Vineis; Olli Raitakari; Santhi K Ganesh; Tien Y Wong; E Shyong Tai; Richard S Cooper; Markku Laakso; Dabeeru C Rao; Tamara B Harris; Richard W Morris; Anna F Dominiczak; Mika Kivimaki; Michael G Marmot; Tetsuro Miki; Danish Saleheen; Giriraj R Chandak; Josef Coresh; Gerjan Navis; Veikko Salomaa; Bok-Ghee Han; Xiaofeng Zhu; Jaspal S Kooner; Olle Melander; Paul M Ridker; Stefania Bandinelli; Ulf B Gyllensten; Alan F Wright; James F Wilson; Luigi Ferrucci; Martin Farrall; Jaakko Tuomilehto; Peter P Pramstaller; Roberto Elosua; Nicole Soranzo; Eric J G Sijbrands; David Altshuler; Ruth J F Loos; Alan R Shuldiner; Christian Gieger; Pierre Meneton; Andre G Uitterlinden; Nicholas J Wareham; Vilmundur Gudnason; Jerome I Rotter; Rainer Rettig; Manuela Uda; David P Strachan; Jacqueline C M Witteman; Anna-Liisa Hartikainen; Jacques S Beckmann; Eric Boerwinkle; Ramachandran S Vasan; Michael Boehnke; Martin G Larson; Marjo-Riitta Järvelin; Bruce M Psaty; Gonçalo R Abecasis; Aravinda Chakravarti; Paul Elliott; Cornelia M van Duijn; Christopher Newton-Cheh; Daniel Levy; Mark J Caulfield; Toby Johnson
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

10.  A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans.

Authors:  Huaixing Li; Wei Gan; Ling Lu; Xiao Dong; Xueyao Han; Cheng Hu; Zhen Yang; Liang Sun; Wei Bao; Pengtao Li; Meian He; Liangdan Sun; Yiqin Wang; Jingwen Zhu; Qianqian Ning; Yong Tang; Rong Zhang; Jie Wen; Di Wang; Xilin Zhu; Kunquan Guo; Xianbo Zuo; Xiaohui Guo; Handong Yang; Xianghai Zhou; Xuejun Zhang; Lu Qi; Ruth J F Loos; Frank B Hu; Tangchun Wu; Ying Liu; Liegang Liu; Ze Yang; Renming Hu; Weiping Jia; Linong Ji; Yixue Li; Xu Lin
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

View more
  12 in total

Review 1.  Recent progress in the genetics of diabetic microvascular complications.

Authors:  Yi-Cheng Chang; Emily Yun-Chia Chang; Lee-Ming Chuang
Journal:  World J Diabetes       Date:  2015-06-10

Review 2.  Genetics of diabetic nephropathy: a long road of discovery.

Authors:  Amy Jayne McKnight; Seamus Duffy; Alexander P Maxwell
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

3.  Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy.

Authors:  Susan B Gurley; Sujoy Ghosh; Stacy A Johnson; Kengo Azushima; Rashidah Binte Sakban; Simi E George; Momoe Maeda; Timothy W Meyer; Thomas M Coffman
Journal:  Diabetes       Date:  2018-07-31       Impact factor: 9.461

Review 4.  The genetics of diabetic complications.

Authors:  Emma Ahlqvist; Natalie R van Zuydam; Leif C Groop; Mark I McCarthy
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

Review 5.  Developing Treatments for Chronic Kidney Disease in the 21st Century.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Semin Nephrol       Date:  2016-11       Impact factor: 5.299

6.  Genetic Variants in Toll-Like Receptor 4 Gene and Their Association Analysis with Estimated Glomerular Filtration Rate in Mexican American Families.

Authors:  Farook Thameem; Sobha Puppala; Vidya S Farook; Balakuntalam S Kasinath; John Blangero; Ravindranath Duggirala; Hanna E Abboud
Journal:  Cardiorenal Med       Date:  2016-05-20       Impact factor: 2.041

7.  Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study.

Authors:  Afshin Parsa; Peter A Kanetsky; Rui Xiao; Jayanta Gupta; Nandita Mitra; Sophie Limou; Dawei Xie; Huichun Xu; Amanda Hyre Anderson; Akinlolu Ojo; John W Kusek; Claudia M Lora; L Lee Hamm; Jiang He; Niina Sandholm; Janina Jeff; Dominic E Raj; Carsten A Böger; Erwin Bottinger; Shabnam Salimi; Rulan S Parekh; Sharon G Adler; Carl D Langefeld; Donald W Bowden; Per-Henrik Groop; Carol Forsblom; Barry I Freedman; Michael Lipkowitz; Caroline S Fox; Cheryl A Winkler; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2016-10-11       Impact factor: 10.121

Review 8.  Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Rev Diabet Stud       Date:  2015-08-10

9.  Evaluation of neurotrophic tyrosine receptor kinase 2 (NTRK2) as a positional candidate gene for variation in estimated glomerular filtration rate (eGFR) in Mexican American participants of San Antonio Family Heart study.

Authors:  Farook Thameem; V Saroja Voruganti; John Blangero; Anthony G Comuzzie; Hanna E Abboud
Journal:  J Biomed Sci       Date:  2015-03-25       Impact factor: 8.410

Review 10.  Pima Indian Contributions to Our Understanding of Diabetic Kidney Disease.

Authors:  Robert G Nelson; William C Knowler; Matthias Kretzler; Kevin V Lemley; Helen C Looker; Michael Mauer; William E Mitch; Behzad Najafian; Peter H Bennett
Journal:  Diabetes       Date:  2021-07-20       Impact factor: 9.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.